Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Boehringer Ingelheim
Accenture
QuintilesIMS
Cantor Fitzgerald
Medtronic
Covington
Citi
Deloitte

Generated: May 20, 2018

DrugPatentWatch Database Preview

REQUIP Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Requip, and when can generic versions of Requip launch?

Requip is a drug marketed by Glaxosmithkline Llc and is included in two NDAs. There are two patents protecting this drug and nine Paragraph IV challenges.

The generic ingredient in REQUIP is ropinirole hydrochloride. There are fourteen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the ropinirole hydrochloride profile page.
Drug patent expirations by year for REQUIP
Pharmacology for REQUIP
Drug ClassNonergot Dopamine Agonist
Mechanism of ActionDopamine Agonists
Synonyms for REQUIP
1,3-Dihydro-4-(2-(dipropylamino)ethyl)-2H-indol-2-one monohydrochloride
2(H)-Indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-, monohydrochloride
2H-Indol-2-one, 1,3-dihydro-4-(2-(dipropylamino)ethyl)-, monohydrochloride
374R208
4-(2-(Dipropylamino)ethyl)-2-indolinone monohydrochloride
4-(2-(Dipropylamino)ethyl)indolin-2-one hydrochloride
4-(2-(Dipropylamino)ethyl)indolin-2-onehydrochloride
4-(2-di-n-propylaminoethyl)-2(3H)-indolone hydrochloride
4-(2-di-n-propylaminoethyl)-2(3H)indolone hydrochloride
4-(2-dipropylaminoethyl)-1,3-dihydroindol-2-one hydrochloride
4-[2-(Di-n-propylamino)ethyl]-2(3H)-indolone Hydrochloride
4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one hydrochloride
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one;hydrochloride
4-[2-(dipropylamino)ethyl]-2,3-dihydro-1H-indol-2-one hydrochloride
4-[2-(dipropylamino)ethyl]indolin-2-one hydrochloride
4CA-1107
91374-20-8
91374-20-8,91374-21-9(freebase)
91374-21-9 (base)
91374-21-9 (Parent)
A843815
AB0009822
ABP000199
AC-735
AC-736
AC1L2ABS
AC1Q3EQJ
ACT02690
Adartrel
AK-59618
AKOS015844988
AN-15584
ANW-58872
BC207366
BS-1020
CCG-213346
CHEBI:8889
CHEMBL1200411
CS-2864
CTK8B7890
D00784
D7ZD41RZI9
DTXSID50238533
EBD38503
EU-0101101
FC0024
FT-0642200
HP-3000
HY-B0623A
I06-0693
JZP-7
KB-80420
KS-000011L6
KS-00002WRZ
LP01101
LS-83828
M-1298
MCULE-8190476072
MFCD01754173
MLS003899234
MolPort-003-987-439
NCGC00094373-01
NCGC00261786-01
NP-201
NVD-434
R 4152
Repreve
Requip (TN)
ReQuip LP
ReQuip PR
ReQuip XR
Ropinirole (hydrochloride)
Ropinirole for peak identification 1, EuropePharmacopoeia (EP) Reference Standard
Ropinirole for peak identification 2, EuropePharmacopoeia (EP) Reference Standard
Ropinirole HCl
Ropinirole hydrochloride
Ropinirole hydrochloride (JAN/USAN)
Ropinirole hydrochloride [USAN:USP]
Ropinirole hydrochloride [USAN]
Ropinirole hydrochloride, EuropePharmacopoeia (EP) Reference Standard
Ropinirole Hydrochloride, pharmaceutical secondary standard; traceable to USP, PhEur
Ropinirole hydrochloride, powder, >=98% (HPLC)
Ropinirole hydrochloride, United States Pharmacopeia (USP) Reference Standard
Ropinirole hydrochloride;
Ropinirole hydrochloride/
Ropinirolehydrochloride
Ropinirolhydrochloride
s3189
SCHEMBL40760
SK&F 101468-A
SK&F-101468-A
SK&F-101468A
SKF 101468 hydrochloride
SKF 101468; 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride
SKF-101468A
SMR001456484
SR-01000076215
SR-01000076215-2
ST24042825
ST51051236
TC-030791
TL8005858
Tox21_501101
UNII-D7ZD41RZI9
XDXHAEQXIBQUEZ-UHFFFAOYSA-N
Z1695926158

US Patents and Regulatory Information for REQUIP

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-001 Sep 19, 1997 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-006 Apr 10, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-005 Oct 31, 2008 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-005 Sep 19, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for REQUIP

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-006 Jan 27, 1999 ➤ Sign Up ➤ Sign Up
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-005 Sep 19, 1997 ➤ Sign Up ➤ Sign Up
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-002 Sep 19, 1997 ➤ Sign Up ➤ Sign Up
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-004 Sep 19, 1997 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for REQUIP
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 3 mg ➤ Subscribe 2009-01-08
➤ Subscribe Extended-release Tablets 6 mg ➤ Subscribe 2009-07-22
➤ Subscribe Extended-release Tablets 12 mg ➤ Subscribe 2009-02-05
➤ Subscribe Extended-release Tablets 3 mg ➤ Subscribe 2009-01-08
➤ Subscribe Extended-release Tablets 8 mg ➤ Subscribe 2008-11-03
➤ Subscribe Extended-release Tablets 4 mg ➤ Subscribe 2008-10-31
➤ Subscribe Extended-release Tablets 2 mg ➤ Subscribe 2008-10-14
➤ Subscribe Tablets 3 mg, 4 mg and 5 mg ➤ Subscribe 2005-02-04
➤ Subscribe Tablets 0.25 mg, 0.5 mg, 1 mg and 2 mg ➤ Subscribe 2004-12-22

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Accenture
Fuji
Deloitte
Boehringer Ingelheim
McKesson
Mallinckrodt
Baxter
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.